Early diagnosis saves lives

We are helping conquer cancer and fibrotic diseases by extracting invaluable clinical insights from patients’ medical images.

We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs. We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients.

We provide invaluable clinical insights where others see only images

We are a game changer in the medical space. Deploying our clinical expertise, proprietary technologies, and data science experience, we generate unprecedented insights from medical images for both drug development and patient care. We bring answers to your concerns and help therapeutic decisions.

Going beyond images

Our imaging solutions make an impact throughout the entire patient journey, from drug development to patient care.

Imaging Services for Oncology Clinical Trials

With iCRO we offer best-in-class end-to-end image management in oncology trials. We provide our global biopharma customers with key data on patients’ response to candidate drugs from phase I through phase III studies. Imaging Lab, our enriched iCRO offering, drives drug development success with transformative AI-powered insights.

End-to-end CADe/CADx software as medical devices

With eyonis™ we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.

The latest from Median

Median Technologies has been selected as a preferred clinical trial imaging services provider for another leading global pharmaceutical company.
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.

Invest in us

Our innovative technology and leading expertise is opening up new possibilities for biopharmaceutical companies and healthcare professionals around the world.

By successfully helping improve the lives of millions, we are delivering value for our investors and partners.

Our company is listed on Euronext Growth and our shareholding structure reflects our global reach, with major shareholders from Europe, USA, and Asia.

Work with us

Being part of Median doesn’t just mean working for a company at the cutting edge of medical imaging. You become part of a team striving to improve outcomes for people suffering from life-threatening diseases. Join us!